CYP4F3 and bulbospinal muscular atrophy: Studies have demonstrated that the progression of SBMA is influenced by serum testosterone levels, with spironolactone inhibiting 17α-hydroxylase activity and cytochrome P-450 content, thus effectively decreasing testosterone synthesis.